A-share issuance

Founded in 2008, RemeGen develops and sells novel drugs in the areas of autoimmunity, oncology, ophthalmology and other major diseases.

FAST NEWS: RemeGen scales back A-share fundraising plan

The Latest: Novel drug maker RemeGen Co. Ltd. (9995.HK; 688331.SH) announced Wednesday that it has reduced its fundraising target through a planned issue of new A-shares from a previous 2.55 billion yuan ($350…
9995.HK 688331.SHG

Recent Articles

RELATED ARTICLES

  1. Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.
    Akeso marks profit milestone with swift rights issue
    9926.HK
  2. BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
  3. Kintor shares plunge after hair-loss drug flops in clinical trials
    9939.HK
  4. Clinical trials come up short again for Alphamab Oncology
    9966.HK
  5. Profit setback for Simcere Pharma in novel drugs quest
    2096.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva